These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 697379)

  • 41. [Index of "unbound" thyroxine in patients with hypercholesterolemia or hypertriglyceridemia treated with clofibrate].
    Felt V; Strasek J; Bednár J
    Cas Lek Cesk; 1972 Sep; 111(40):929-31. PubMed ID: 4628030
    [No Abstract]   [Full Text] [Related]  

  • 42. [Study of the antilipemic effect of etofibrate (Lipo-Merz)].
    Słowińska R; Bochenek W; Unlot J
    Pol Tyg Lek; 1983 Apr; 38(17):529-32. PubMed ID: 6356087
    [No Abstract]   [Full Text] [Related]  

  • 43. Potential hypolipidemic agents. XIX. Synthesis and lipid-lowering properties of thiophene derivatives related to clofibrate.
    Gronowitz S; Svenson R; Bondesson G; Magnusson O; Stjernström NE
    Acta Pharm Suec; 1978; 15(5):361-7. PubMed ID: 747094
    [No Abstract]   [Full Text] [Related]  

  • 44. Effect of probucol on triton induced hyperlipidemias in CFY rats.
    Krishnamurthy A; Thapar GS; Shridhar DR
    Artery; 1985; 13(2):87-94. PubMed ID: 4084069
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Serum gas chromatographic determination of hypolipemic agents derived from clofibric acid].
    Cailleux A; Allain P
    Therapie; 1976; 31(5):631-6. PubMed ID: 1013955
    [No Abstract]   [Full Text] [Related]  

  • 46. [Therapy of hyperlipidemia].
    Müller G
    Dtsch Gesundheitsw; 1971 Oct; 26(43):2020-4. PubMed ID: 4947270
    [No Abstract]   [Full Text] [Related]  

  • 47. [Comparison of the hypolipemic effect of nicotinic acid and of some substituted thiazolic acids. Study on the serum of rat treated with triton WR-1339].
    Lechat P; Freyss-Beguin M; Boime A; Mathieu-Levy N; van Brussel E
    Therapie; 1971; 26(3):497-509. PubMed ID: 5113802
    [No Abstract]   [Full Text] [Related]  

  • 48. Gemfibrozil and clofibrate in the treatment of hyperlipidaemias. A comparative trial.
    Eisalo A; Manninen V
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):44-6. PubMed ID: 798196
    [No Abstract]   [Full Text] [Related]  

  • 49. [Toxic myopathy due to hypolipemic agents].
    Bourrier P; Subra JF; Chennebault JM; Spiesser R; Laine P
    Therapie; 1990; 45(4):360. PubMed ID: 2399525
    [No Abstract]   [Full Text] [Related]  

  • 50. [Drugs which influence plasma fatty acids and lipoproteins. Opinion of Prof. Rodolfo Paoletti].
    Salvati A
    Minerva Med; 1973 Sep; 64(62):3256-9. PubMed ID: 4359661
    [No Abstract]   [Full Text] [Related]  

  • 51. [Pharmacology and collateral effects of ITA 104].
    Giráldez A; Bermejo P; Bargalló MA; Beascoa E; Zapatero J; Llenas J; Gras J; Bruseghini L
    Arch Farmacol Toxicol; 1978 Apr; 4(1):139-42. PubMed ID: 697381
    [No Abstract]   [Full Text] [Related]  

  • 52. [Toxicological and pharmacological studies on a new drug: pirfibrate (EL-466) (author's transl)].
    de la Fuente R; Santos M
    Arch Farmacol Toxicol; 1980 Dec; 6(3):255-64. PubMed ID: 7305456
    [No Abstract]   [Full Text] [Related]  

  • 53. Influence of plafibride, an antiplatelet and hypolipemic agent, on prostacyclin and thromboxane synthesis, 3',5'-cyclic AMP phosphodiesterase activity and serum clearance of a lipid emulsion.
    Vilageliu J; Freixes J; Giráldez A; Bermejo P; Basi N; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1805-7. PubMed ID: 6274363
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Plafibride--is it an effective drug as a hypolipemic agent?].
    Joven J
    Med Clin (Barc); 1985 Apr; 84(15):632. PubMed ID: 3999857
    [No Abstract]   [Full Text] [Related]  

  • 55. [Atorvastatin . A new generation of hypolipemic agents?].
    Azanza JR; Sádaba B; Quetglas EG
    Rev Med Univ Navarra; 1998; 42(1):51-5. PubMed ID: 10420957
    [No Abstract]   [Full Text] [Related]  

  • 56. Clinical trials of plafibride in geriatric patients.
    Demichelis Genesio MA; Bracons R; Vicens B; Zapatero J; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1852-5. PubMed ID: 7198465
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Pharmacology and toxicology of etofylline clofibrate].
    Sterner W; Korn WD
    Arzneimittelforschung; 1980; 30(11b):2023-31. PubMed ID: 7194053
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A clofibrate controlled trial of gemfibrozil in the treatment of hyperlipidaemias.
    Tuomilehto J; Salonen J; Kuuisto P; Virtamo J; Manninen V; Mälkönen M
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):38-40. PubMed ID: 798195
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The hypolipidaemic effect of gemfibrozil (CI-719) in laboratory animals.
    Rodney G; Uhlendorf P; Maxwell RE
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):6-10. PubMed ID: 828263
    [No Abstract]   [Full Text] [Related]  

  • 60. [Carbohydrate metabolism in bezafibrate therapy. Controlled study of glibenclamide-treated diabetics with hyperlipidemia].
    Janka HU; Standl A; Holler HD; Mehnert H
    MMW Munch Med Wochenschr; 1982 May; 124(21):535-7. PubMed ID: 6810123
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.